Form 4: FATE CEO Sells Shares for Tax Obligations

FATE Therapeutics' President and CEO, Bahram Valamehr, sold 14,466 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Bahram Valamehr, President and CEO, and a Director of FATE Therapeutics Inc. (FATE), reported a transaction on August 4, 2025.
• The transaction involved the disposition of 14,466 shares of common stock.
• The shares were sold at a weighted average price of $1.0643 per share, with prices ranging from $1.04 to $1.07.
• This sale was a 'sell-to-cover' transaction, automatically executed to satisfy tax withholding obligations upon the vesting of 25,000 shares of Restricted Stock Units (RSUs).
• The RSUs were originally granted to Mr. Valamehr on July 29, 2024.
• Following this transaction, Mr. Valamehr beneficially owns 334,898 shares of common stock directly.
• The sale was not at the discretion of the reporting person, as it was executed pursuant to an irrevocable election under a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports a routine, non-discretionary 'sell-to-cover' transaction for tax purposes, which does not typically indicate a change in management's confidence or company fundamentals.

Positives

• The transaction was a non-discretionary 'sell-to-cover' to meet tax obligations, indicating a routine event rather than a discretionary sale by management.

Negatives

• No specific negative aspects are highlighted as this is a routine, non-discretionary transaction for tax purposes.

Future Outlook

The filing does not provide any forward-looking statements or guidance beyond the details of the reported transaction.

Management Comments

• The required number of shares were sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25,000 shares of Common Stock underlying RSUs granted on July 29, 2024.
• These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through 'sell-to-cover' transactions and were not made at the discretion of the Reporting Person.

Industry Context

This Form 4 filing reports a routine insider transaction common across all industries, particularly for executives receiving equity compensation like RSUs. It does not provide specific insights into broader biotechnology industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company outlook or management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine, non-discretionary 'sell-to-cover' transaction by the CEO to satisfy tax obligations related to RSU vesting. Such transactions are common and do not typically reflect management's view on the company's future prospects or fundamental value. Therefore, this specific filing does not provide new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

FATE Therapeutics, FATE, Bahram Valamehr, Insider Trading, Form 4, Sell-to-Cover, RSU Vesting, Executive Compensation, Biotechnology